StreetInsider.com News Articles

Craig-Hallum Downgrades Personalis (PSNL) to Hold

Mon, 24 Aug 2026 08:53:31 -0400

Craig-Hallum analyst John Wilkin downgraded Personalis (NASDAQ: PSNL) from Buy to Hold.

For an analyst ratings summary and ratings history on Personalis click here. For more ratings news on Personalis click here.

Shares of Personalis closed at $18.38 yesterday.

Form 8-K Personalis, Inc. For: Aug 20

Thu, 20 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260820/26956778.html

Form 8-K Personalis, Inc. For: Aug 20

Thu, 20 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260820/26956778.html

Form SCHEDULE 13G/A Personalis, Inc. Filed by: AMERIPRISE FINANCIAL INC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926152.html

Form SCHEDULE 13G/A Personalis, Inc. Filed by: AMERIPRISE FINANCIAL INC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926152.html

Form SCHEDULE 13G/A Personalis, Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26925187.html

Form SCHEDULE 13G/A Personalis, Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26925187.html

Personalis, Inc. (PSNL) Misses Q2 EPS by 4c

Tue, 04 Aug 2026 17:12:51 -0400

Personalis, Inc. (NASDAQ: PSNL) reported Q2 EPS of ($0.30), $0.04 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $22.4 million versus the consensus estimate of $16.89 million.

For earnings history and earnings-related data on Personalis, Inc. (PSNL) click here.

Form 10-Q Personalis, Inc. For: Jun 30

Tue, 04 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260804/26866403.html

Form 10-Q Personalis, Inc. For: Jun 30

Tue, 04 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260804/26866403.html

Form 8-K Personalis, Inc. For: Aug 04

Tue, 04 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260804/26865981.html

Form 8-K Personalis, Inc. For: Aug 04

Tue, 04 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260804/26865981.html

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.

Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO

Personalis Reports Second Quarter Results and Recent Highlights

Tue, 04 Aug 2026 16:01:00 -0400

Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2

Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million

Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.
Second Quarter and Recent Strategic and Operational Highlights

Secured Medicare Coverage for IO